feedback

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: July 15, 2019
Expires: July 14, 2020
60 minutes to complete

Accredited By

Target Audience

This activity is designed for general neurologists and headache specialists. Other healthcare professionals, including physician assistants, nurse practitioners, nurses, and pharmacists, who treat patients with headache may also benefit from participation in the educational activity.

Learning Objectives

Upon completion of this activity, participants should be able to:

  1. Describe new advances in the pathophysiology of migraine, a chronic neurologic disease.
  2. Develop treatment plans in line with standards of practice for acute and preventive management of episodic and chronic migraine.
  3. Discuss unmet patient needs and burden of episodic and chronic migraine.
  4. Analyze safety and efficacy data for emerging therapies in acute and preventive treatment of migraine relative to current standards and clinically meaningful outcomes.

Activity Description

The thinking around both preventive and acute treatment of migraine is undergoing a radical change as new therapies emerge that target varied routes, some specific to known mechanisms of migraine pathophysiology. From new classes of treatment to emerging therapies and neuromodulatory devices, headache specialist and general neurologist, Stewart J. Tepper, MD, and Ana Felix, MD, FAAN, team up to provide a practical update for practicing clinicians on key treatment advances that are transforming migraine care.

Statement of Educational Need

With the recent approvals, neurologists are faced with two challenges: staying abreast of the rapidly expanding evidence base to inform acute and preventive treatment of migraine (knowledge-based gaps) and interpreting data of approved and investigational therapies to best guide clinical decision-making (competency-based gaps).

Agenda

The New Era of Migraine Treatment
Cases in Episodic and Chronic Migraine

Faculty

Stewart J. Tepper, MD
Professor of Neurology,
Geisel School of Medicine at Dartmouth
Director, Dartmouth Headache Center
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire


Ana Felix, MD, FAAN
Neurologist,
Assistant Professor,
Department of Internal Medicine
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina


Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Faculty: Stewart J. Tepper, MD, has received salary from Dartmouth-Hitchcock Medical Center and from the American Headache Society and royalties from Springer; he has been a consultant or on an advisory board for Acorda Therapeutics, Alder BioPharmaceuticals, Alexza Pharmaceuticals, Inc, Allergan, Alphasights, Amgen, Autonomic Technologies, Inc., Axsome Therapeutics, Cefaly, Charleston Laboratories, Inc., DeepBench, Dr. Reddy’s Laboratories Ltd., electroCore, LLC, Eli Lilly and Company, eNeura, GLG Pharma, Guidepoint Global, LLC, Magellan Rx Management, Neurolief Ltd., Nordic BioTech, Novartis, Pfizer, Scion Neurostim, LLC, Slingshot Insights, Supernus Pharmaceuticals, Teva Pharmaceutical Industries Ltd., and Zosano Pharma Corporation; Dr. Tepper has contracted research for Alder BioPharmaceuticals, Allergan, Amgen, Autonomic Technologies, Inc., Dr. Reddy’s Laboratories, Ltd., electroCore, LLC, eNeura, Neurolief, Novartis, Scion Neurostim, LLC, Teva Pharmaceutical Industries Ltd., and Zosano Pharma Corporation; he has ownership interest in Autonomic Technologies, Inc.
  • Planner (Forefront Collaborative): Lily Zurkovsky, PhD, has disclosed that she has personal stock in Teva Pharmaceutical Industries Ltd.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this continuing education activity:

  • Faculty: Ana Felix, MD, FAAN
  • Planner (Forefront Collaborative): Krista Jaworski

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Forefront Collaborative designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

Participants must complete and submit the online CME evaluation form at the conclusion of the activity and achieve a passing score of 80%. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.

Content Review Statement

The content of this activity was independently peer reviewed. The reviewer of this activity has no relevant financial relationships to disclose.

This continuing medical education activity will include reference to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions about the Activity

Krista_jaworski@forefrontcollab.com
812-340-4274

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.